Monopar to Participate in the Radiopharma Forum by the Lake 2023
WILMETTE, Ill., June 21, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing...
Day: June 21, 2023
InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients
Gohibic is now commercially available for hospitals in the U.S.Gohibic can be used under an Emergency Use Authorization (EUA) granted...
Jonathan Milner issues Open Letter to shareholders of Abcam plc
Jonathan Milner issues Open Letter to shareholders of Abcam plc Responds to Company’s assertions in its statement on 20 June...
Teleflex Announces Partnership with Insighters Medical for Exclusive Distribution of the Insighters® Video Laryngoscope System
WAYNE, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today...
570 000 Orion Corporation A shares converted into B shares
ORION CORPORATION STOCK EXCHANGE RELEASE - OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE21 JUNE 2023 at 10.15...
IBT continues to recruit prematurely born infants to The Connection Study following a planned safety analysis.
In accordance with the study protocol, the independent Data Monitoring Committee (DMC) has performed the final planned safety analysis of...
Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023
Treatment was generally well tolerated with continued HBsAg declines in some patients WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) --...
Essential Pharma appoints Lee Morley as Non-Executive Director to the Board
Essential Pharma appoints Lee Morley as Non-Executive Director to the Board Zug, Switzerland & Egham, UK – 21 June 2023...
Sequana Medical announces additional data on safety, quality of life and survival from North American pivotal alfapump® study (POSEIDON)
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION21 June 2023, 07:00 am CEST Data presented at EASL Congress 2023 alfapump was effective...
argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis
VYVGART Hytrulo Bottle VYVGART Hytrulo Bottle VYVGART Hytrulo Logo VYVGART Hytrulo Logo Tim Van Hauwermeiren argenx CEO, Tim Van Hauewermeiren...